Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2b - Enzon/Merck & Co.

Drug Profile

Peginterferon alfa-2b - Enzon/Merck & Co.

Alternative Names: Cylatron; Interferon-alpha-2b macrogol; Intron A Peg; PEG interferon-alpha-2b; PEG-Intron; PEG-Intron A; PEG-Intron-A; Pegatron; PEGIFN; PegIntron; Pegintron; Pegtron; Pegylated IFN alfa-2b; Pegylated IFN-alpha 2b; Pegylated interferon-alpha-2b; pIFN - alpha 2b; Polyethylene glycol interferon-alpha-2b; SCH 54031; Sylatron; ViraferonPeg

Latest Information Update: 06 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Hoosier Cancer Research Network; Merck & Co; Novartis; Schering-Plough; VU University Medical Center; Wistar Institute
  • Class Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
  • Mechanism of Action Interferon-alpha replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Malignant melanoma
  • Phase II Cholangiocarcinoma; HIV infections
  • Discontinued Chronic myeloid leukaemia; Multiple sclerosis; Polycythaemia vera; Solid tumours

Most Recent Events

  • 03 Mar 2024 Pharmacodynamics data from the phase I BEAT-2 trial in HIV-1 infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)
  • 28 May 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (SC, Injection)
  • 19 Feb 2023 Efficacy data from the phase I BEAT-2 trial in HIV-1 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023 (CROI-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top